Citius: Positive Results from Solid Tumor Study Combo

 

Preclinical study demonstrates that adding LYMPHIR to anti-PD-1 treatment augments anti-tumor activity and improves overall survival compared to monotherapy alone by transiently depleting Tregs in the tumor microenvironment https://www.biospace.com/article/releases/citius-pharmaceuticals-announces-publication-in-frontiers-of-immunology-of-positive-results-from-solid-tumor-study-of-lymphir-in-combination-with-checkpoint-inhibitor/